Skip to main content

Advertisement

SpringerLink
Log in

Management of regional citrate anticoagulation in pediatric high-flux dialysis: activated coagulation time versus post-filter ionized calcium

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Recent years has seen an increasing use of regional citrate anticoagulation in pediatric dialysis. Several approaches have been described for monitoring anticoagulation in the extracorporeal circuit, such as serum citrate levels, post-filter ionized calcium (iCa), and activated coagulation time (ACT). However, no standard recommendations have yet been established for applying any of these parameters, especially for iCa. The objective of this retrospective analysis was to establish adequate coagulation management using post-filter iCa values. Normal values for ACTester-based ACT were established using a group of 64 children who were divided into two subgroups, with one subgroup comprising children without chronic kidney disease or coagulation disorder (age 1.2–17.5 years, median 9.7 years) and one consisting of 32 uremic patients (age 0.6–17.5 years, median 13.7 years). In a second group of 13 patients (aged 7–17 years), all of whom were undergoing high-flux dialysis (HD) with regional citrate anticoagulation (RCA), we assessed 73 post-filter blood samples for ionized calcium and ACT. A receiver operating characteristic graph was used to identify the iCa threshold needed to achieve adequate anticoagulation. Normal values for ACT were 90 s [2 standard deviations (SD) 72–109] in healthy children and 94 s (2 SD 75–113) in the uremic children. There was no statistically significant difference between the groups. In the children undergoing HD with RCA, the post-filter iCa level correlated with ACT (r = −0.94, p < 0.001). A post-filter iCa level of ≤0.30 mmol/l reliably predicted an ACT >120 s. Our citrate protocol [citrate 3% rate (ml/h) ≈ blood flow rate (ml/min) × 2] meets the established criteria with a high sensitivity. Based on these results, we conclude that the post-filter iCa level can be reliably used for the management of extracorporeal anticoagulation with citrate in pediatric HD. We recommend the application of our citrate prescription protocol in the setting of pediatric intermittent hemodialysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

ACD:

Anticoagulant citrate dextrose

ACT:

Activated coagulation time

CRRT:

Continuous renal replacement therapy

iCa:

Ionized calcium

iHD:

Intermittent hemodialysis

PTT:

Partial thromboplastin time

RCA:

Regional citrate anticoagulation

References

  1. Morita Y, Johnson RW, Dorn RE, Hall DS (1961) Regional anticoagulation during hemodialysis using citrate. Am J Med Sci 242:32–43

    Article  CAS  PubMed  Google Scholar 

  2. Pinnick RV, Wiegmann TB, Diederich DA (1983) Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 308:258–261

    Article  CAS  PubMed  Google Scholar 

  3. Mehta R, McDonald B, Aguilar M, Ward DM (1990) Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 38:976–981

    Article  CAS  PubMed  Google Scholar 

  4. Gubensek J, Buturovic-Ponikvar J, Ponikvar R (2007) Regional citrate anticoagulation for single-needle hemodialysis: a prospective clinical study. Blood Purif 25:454–456

    Article  CAS  PubMed  Google Scholar 

  5. Schneider M, Thomas K, Liefeldt L, Kindgen-Milles D, Peters H, Neumayer HH, Morgera S (2007) Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: a prospective study. Clin Nephrol 68:302–307

    CAS  PubMed  Google Scholar 

  6. Bunchman TE, Maxvold NJ, Barnett J, Hutchings A, Benfield MR (2002) Pediatric hemofiltration. Normocarb dialysate solution with citrate anticoagulation. Pediatr Nephrol 17:150–154

    Article  PubMed  Google Scholar 

  7. Bunchman TE, Maxvold NJ, Brophy PD (2003) Pediatric convective hemofiltration: Normocarb replacement fluid and citrate anticoagulation. Am J Kidney Dis 42:1248–1252

    Article  PubMed  Google Scholar 

  8. Chadha V, Garg U, Warady BA, Alon US (2002) Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr Nephrol 17:819–824

    Article  PubMed  Google Scholar 

  9. Elhanan N, Skippen P, Nuthall G, Krahn G, Seear M (2004) Citrate anticoagulation in pediatric continuous venovenous hemofiltration. Pediatr Nephrol 19:208–212

    Article  PubMed  Google Scholar 

  10. Symons JM, Chua AN, Somers MJ, Baum MA, Bunchman TE, Benfield MR, Brophy PD, Blowey D, Fortenberry JD, Chand D, Flores FX, Hackbarth R, Alexander SR, Mahan J, McBryde KD, Goldstein SL (2007) Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry. Clin J Am Soc Nephrol 2:732–738

    Article  PubMed  Google Scholar 

  11. Ward DM (1997) The approach to anticoagulation in patients treated with extracorporeal therapy in the intensive care unit. Adv Ren Replace Ther 4:160–173

    CAS  PubMed  Google Scholar 

  12. Ataullakhanov F, Pohilko A, Sinauridze E (1994) Calcium threshold in human plasma clotting kinetics. Thromb Res 75:383–394

    Article  CAS  PubMed  Google Scholar 

  13. Calatzis A, Toepfer M, Schramm W, Spannagl M, Schiffl H (2001) Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron 89:233–236

    Article  CAS  PubMed  Google Scholar 

  14. Hattersley PG (1966) Activated coagulation time of whole blood. JAMA 196:436–440

    Article  CAS  PubMed  Google Scholar 

  15. Taneja R, Fernandes P, Marwaha G, Cheng D, Bainbridge D (2008) Perioperative coagulation management and blood conservation in cardiac surgery: a Canadian Survey. J Cardiothorac Vasc Anesth 22:662–669

    Article  PubMed  Google Scholar 

  16. Slight RD, Buell R, Nzewi OC, McClelland DB, Mankad PS (2008) A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 22:47–52

    Article  CAS  PubMed  Google Scholar 

  17. Martindale SJ, Shayevitz JR, D’Errico C (1996) The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth 10:458–463

    Article  CAS  PubMed  Google Scholar 

  18. Hattersley PG (1971) The activated coagulation time of whole blood as a routine pre-operative sceening test. Calif Med 114:15–18

    CAS  PubMed  Google Scholar 

  19. Siskin GP, Reiner E, Stainken BF, Dowling K, Dolen EG, Quarfordt S, Albons G (2001) Activated clotting time as a screening test prior to catheter-based cardiovascular procedures. Catheter Cardiovasc Interv 54:191–195

    Article  CAS  PubMed  Google Scholar 

  20. Davenport A (2003) Anticoagulation options for pediatric hemodialysis. Hemodial Int 7:168–176

    Article  PubMed  Google Scholar 

  21. Rani TR, Gopinath R (2008) An unusual cause of a prolonged activated coagulation time during cardiac surgery: congenital hypofibrinogenemia. J Cardiothorac Vasc Anesth 22:725–726

    Article  PubMed  Google Scholar 

  22. Chang RJ, Doherty TM, Goldberg SL (1998) How does warfarin affect the activated coagulation time? Am Heart J 136:477–479

    Article  CAS  PubMed  Google Scholar 

  23. Stefanidis I, Hägel J, Maurin N (1995) Influence of coagulation parameters on filter running time during continuous venovenous hemofiltration. Contrib Nephrol 116:145–149

    CAS  PubMed  Google Scholar 

  24. Lord H, Jean N, Dumont M, Kassis J, Leblanc M (2002) Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol 22:58–66

    Article  PubMed  Google Scholar 

  25. Hörl WH (2006) Thrombocytopathy and bleeding complications in Uremia. Wien Klin Wochenschr 118:134–150

    Article  PubMed  CAS  Google Scholar 

  26. Nuthall G, Skippen P, Daoust C, Al-Jofan F, Seear M (2002) Citrate anticoagulation in a piglet model of pediatric continuous renal replacement therapy. Crit Care Med 30:900–903

    Article  CAS  PubMed  Google Scholar 

  27. Bakker AJ, Boerma EC, Keidel H, Kingma P, van der Voort PH (2006) Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous hemofiltration: use of ionized and total/ionized calcium. Clin Chem Lab Med 44:962–966

    Article  CAS  PubMed  Google Scholar 

  28. Opatrný K, Richtrová P, Polanská K, Wirth J, Sefrna F, Brandl M, Falkenhagen D (2007) Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis. Artif Organs 31:200–207

    Article  PubMed  CAS  Google Scholar 

  29. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Nephrology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany

    Martin Kreuzer, Thurid Ahlenstiel, Nele Kanzelmeyer, Jochen H. H. Ehrich & Lars Pape

  2. Department of Pediatric Nephrology, Hepatology and Metabolic Diseases, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany

    Martin Kreuzer

Authors
  1. Martin Kreuzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thurid Ahlenstiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nele Kanzelmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jochen H. H. Ehrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lars Pape
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Kreuzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kreuzer, M., Ahlenstiel, T., Kanzelmeyer, N. et al. Management of regional citrate anticoagulation in pediatric high-flux dialysis: activated coagulation time versus post-filter ionized calcium. Pediatr Nephrol 25, 1305–1310 (2010). https://doi.org/10.1007/s00467-010-1483-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-010-1483-4

Keywords

Search

Navigation